Q3 Interim Report January – March 2020
Opening remarks Hamlet Pharma can report significant progress during the third quarter of the financial year 2019-2020. In February, the company raised 12.937 million SEK by issuing subscription warranties. In March, Hamlet Pharma received a major EU grant in strong international competition. The company was granted about 23 million SEK from the EIC Accelerator fund of the Horizon 2020 program. The EU grant is a signifcant quality stamp, confirming the company’s acheivements and future potential. The EU program is awarded to strengthen further clinical research, pharmaceutical